BOC Sciences Becomes the Largest PseudoUridine Supplier in the World
BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world.
Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has strengthened its supply capacity of pseudoUridine and derivatives to ease the pressure on the global supply of vaccine raw materials.
BOC Sciences has been known for its strong ability in the development, design, synthesis and production of nucleosides and nucleotides over the years. With its strong cGMP platform and highly-skilled research team, BOC Sciences can supply nucleotide products ranging from milligrams to kilograms, or even hundreds of kilograms. Among BOC Sciences's numerous nucleotide products, pseudoUridine and N1-MethylpseudoUridine have become superstar products due to their important roles in vaccine development and production.
PseudoUridine
PseudoUridine has a subtle but significant effect on the nearby sugar phosphate backbone and enhances base accumulation. It is considered to be a regulator of the latent process of the human immunodeficiency virus (HIV) infection. In addition to pseudoUridine, pseudoUridine derivatives such as 1-methylpseudoUridine, 3-methylpseudoUridine, 2'-O-methylpseudoUridine and ultramodified residue 1 -Methyl-3-(3-amino-3-carboxypropyl) pseudoUridine are also popular products of BOC Sciences.
N1-MethylpseudoUridine
The coronavirus has inspired effective vaccine development activities. N1-methylpseudoUridine is an RNA modification that can be used to improve the safety and effectiveness of the COVID-19 messenger RNA vaccine. As a well-known supplier of pharmaceutical raw materials in the industry, BOC Sciences has been committed to producing COVID-19 mRNA vaccine raw materials with high quality. N1-methylpseudoUridine, one of the raw materials for the COVID-19 mRNA vaccine, has recently become one of the best-selling products of BOC Sciences. In mRNA vaccines, the unnatural RNA nucleobase N1-methylpseudoUridine can enhance immune evasion and protein production. N1-methylpseudoUridine from BOC Sciences has been contributing to the current production of COVID-19 mRNA vaccines.
Furthermore, a wealth of pseudoUridine derivatives are available at BOC Sciences, such as phosphate pseudoUridine and phosphoramidite pseudoUridine. PseudoUridine series products can be applied to RNA modification. Its pseudoUridine series products can also be applied in the production of oligonucleotides.
BOC Sciences will be invited to attend the TIDES USA: Oligonucleotide & Peptide Therapeutics Conference which is to take place from September 20th through 23th at the Boston Convention and Exhibition Center.
For more information about BOC Sciences's pseudoUridine and derivatives, please visit the website: https://nucleotech.bocsci.com.
About BOC Sciences
BOC Sciences’s research team focuses on research in various industries, such as pharmaceuticals, chemistry, and life sciences. For more than a decade, BOC Sciences has been committed to offering strategies and solutions to help solve the industry's most pressing drug development problems, becoming the world's leading pseudoUridine supplier with the largest production capacity to promote vaccine development.
Related news
-
Creative Proteomics Lipidomics Launches Exosomes Lipidomics Service to Study the Biological Characteristics of Vesicles
Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population health, the food industry, etc. Creative Proteomics Lipidomics has recently announced the launch of Exosomes Lipidomics...
-
CD Genomics: The Biomedical Bioinformatics Platform Unveils Biomarker and Target Discovery Data Analysis Service
The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the launch of biomarker and target discovery service for disease identification, early diagnosis and prevention, and monitoring...
-
Ribo-Seq Service Now Available on CD Genomics’s RNA Solutions Platforms
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Ribo-Seq to its offerings. Ribo-Seq, also known as ribosome footprinting, is a method for determining which mRNAs are actively translated by using specializ...
-
CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Whole Transcriptome Sequencing to its offerings. Now scientists and researchers worldwide can easily obtain whole transcriptome sequencing needed in their...
-
Thermo Fisher Scientific Showcases Investment and Innovation During CPhI Worldwide 2021
At CPhI Worldwide 2021, Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics. CPhI 2021 begins with a virtual conference through November 5, 2021 and an in-person live event and exhibition in Milan, Italy from November 9 to 11, 2021, Thermo Fisher Booth #4G10. "Thermo Fisher...
Customer comments
No comments were found for BOC Sciences Becomes the Largest PseudoUridine Supplier in the World. Be the first to comment!